Publications

Li D, Toh HC, Merle P, Tsuchiya K, Hernandez S, Verret W, Nicholas A, Kudo M: Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer 2022. doi: 10.1159/000525671

Shuen TWH, Alunni-Fabbroni M, Öcal E, Malfertheiner P, Wildgruber M, Schinner R, Pech M, Benckert J, Sangro B, Kuhl C, Gasbarrini A, Chow PKH, Toh HC, Ricke J. Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. Clin Cancer Res. 2022 Sep 1;28(17):3890-3901. doi: 10.1158/1078-0432.CCR-22-0569. PMID: 35763041.

Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. PMID: 35739268.

Chen S, Bin Abdul Rahim AA, Wang WW, Cheong R, Prabhu AV, Tan JZY, Naing MW, Toh HC, Liu D. In-situ scalable manufacturing of Epstein-Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA). Sci Rep. 2022 Apr 29;12(1):7045. doi: 10.1038/s41598-022-11015-z. PMID: 35487951; PMCID: PMC9054749.

Nguyen PHD, Wasser M, Tan CT, Lim CJ, Lai HLH, Seow JJW, DasGupta R, Phua CZJ, Ma S, Yang J, Suthen SD, Tam WL, Lim TKH, Yeong J, Leow WQ, Pang YH, Soon G, Loh TJ, Wan WK, Chan CY, Cheow PC, Toh HC, Kow A, Dan YY, Kam JH, Iyer S, Madhavan K, Chung A, Bonney GK, Goh BKP, Fu N, Yu VC, Zhai W, Albani S, Chow PKH, Chew V. Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. Nat Commun. 2022 Mar 17;13(1):1441. doi: 10.1038/s41467-022-29122-w. PMID: 35301339.

Suthen S, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, Wan WK, Pang YH, Soon G, Cheow PC, Kam JH, Iyer S, Kow A, Tam WL, Shuen TWH, Toh HC, Dan YY, Bonney GK, Chan CY, Chung A, Goh BKP, Zhai W, Ginhoux F, Chow PKH, Albani S, Chew V. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 2022 Feb 20. doi: 10.1002/hep.32419. Epub ahead of print. PMID: 35184329.

Zhai W, Lai H, Kaya NA, Chen J, Yang H, Lu B, Lim JQ, Ma S, Chew SC, Chua KP, Alvarez JJS, Chen PJ, Chang MM, Wu L, Goh BKP, Chung AY, Chan CY, Cheow PC, Lee SY, Kam JH, Kow AW, Ganpathi IS, Chanwat R, Thammasiri J, Yoong BK, Ong DB, de Villa VH, Dela Cruz RD, Loh TJ, Wan WK, Zeng Z, Skanderup AJ, Pang YH, Madhavan K, Lim TK, Bonney G, Leow WQ, Chew V, Dan YY, Tam WL, Toh HC, Foo RS, Chow PK. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Natl Sci Rev. 2021 Oct 29;9(3):nwab192. doi: 10.1093/nsr/nwab192. PMID: 35382356; PMCID: PMC8973408.

Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Oct 22:S2468-1253(21)00305-8. doi: 10.1016/S2468-1253(21)00305-8. Epub ahead of print. PMID: 34695377

Han S, Tay JK, Loh CJL, Chu AJM, Yeong JPS, Lim CM, Toh HC. Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies. Front Immunol. 2021 Dec 10;12:734293. doi: 10.3389/fimmu.2021.734293. PMID: 34956172; PMCID: PMC8702733.

Zhao Y, Wang J, Liu WN, Fong SY, Shuen TWH, Liu M, Harden S, Tan SY, Cheng JY, Tan WWS, Chan JKY, Chee CE, Lee GH, Toh HC, Lim SG, Wan Y, Chen Q. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model. Hepatology. 2021 Sep;74(3):1395-1410. doi: 10.1002/hep.31812. PMID: 33738839

Wang G, Mudgal P, Wang L, Shuen TWH, Wu H, Alexander PB, Wang WW, Wan Y, Toh HC, Wang XF, Li QJ. TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma. Oncoimmunology. 2021 Aug 2;10(1):1955545. doi: 10.1080/2162402X.2021.1955545. PMID: 34377592; PMCID: PMC8331028

Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer. 2021 Jun;10(3):224-239. doi: 10.1159/000514400. Epub 2021 Apr 7. PMID: 34239809; PMCID: PMC8237792

Hopkins R, Xiang W, Marlier D, Au VB, Ching Q, Wu LX, Guan R, Lee B, Chia WK, Wang WW, Wee J, Ng J, Cheong R, Han S, Chu A, Chee CL, Shuen T, Podinger M, Lezhava A, Toh HC^, Connolly JE^. Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma. Mol Ther. 2021 Feb 3;29(2):734-743. doi: 10.1016/j.ymthe.2020.09.040. Epub 2020 Sep 30. PMID: 33038324; PMCID: PMC7854281 (^co-corresponding authors)

Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021 Feb;28(1-2):5-17. doi: 10.1038/s41417-020-0183-x. Epub 2020 May 27. PMID: 32457487; PMCID: PMC7886651

Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M, Lai L, Tam WL, Lim TKH, Wan WK, Loh T, Leow WQ, Pang YH, Chan CY, Lee SY, Cheow PC, Toh HC, Ginhoux F, Iyer S, Kow AWC, Young Dan Y, Chung A, Bonney GK, Goh BKP, Albani S, Chow PKH, Zhai W, Chew V. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat Commun. 2021 Jan 11;12(1):227. doi: 10.1038/s41467-020-20171-7. Erratum in: Nat Commun. 2021 Feb 23;12(1):1372. PMID: 33431814; PMCID: PMC7801667

Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, Tan C, Hopkins R, Connolly J, Shuen TWH, Toh HC. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel). 2020 Nov 17;12(11):3404. doi: 10.3390/cancers12113404. PMID: 33212880; PMCID: PMC7698436

Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh BC, Wong ALA. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules. 2020 Oct 20;25(20):4831. doi: 10.3390/molecules25204831. PMID: 33092283; PMCID: PMC7588013

Sharma A, Seow JJW, Dutertre CA, Pai R, Blériot C, Mishra A, Wong RMM, Singh GSN, Sudhagar S, Khalilnezhad S, Erdal S, Teo HM, Khalilnezhad A, Chakarov S, Lim TKH, Fui ACY, Chieh AKW, Chung CP, Bonney GK, Goh BK, Chan JKY, Chow PKH, Ginhoux F, DasGupta R. Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell. 2020 Oct 15;183(2):377-394.e21. doi: 10.1016/j.cell.2020.08.040. Epub 2020 Sep 24. PMID: 32976798

Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol. 2020 Sep 30;11:568759. doi: 10.3389/fimmu.2020.568759. PMID: 33117354; PMCID: PMC7561368

Han S, Shuen TWH, Wang WW, Nazim E, Toh HC. Tailoring precision immunotherapy: coming to a clinic soon? ESMO Open. 2020;5 Suppl 1(Suppl 1):e000631. doi: 10.1136/esmoopen-2019-000631. Epub 2020 Sep 30. PMID: 33558033; PMCID: PMC7046383

Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020 Aug;8(2):e000987. doi: 10.1136/jitc-2020-000987. PMID: 32847986; PMCID: PMC7451957
Li LJ, Chong Q, Wang L, Goh BC, Soo RA. Different treatment efficacies and side effects of cytotoxic chemotherapy. J Thorac Dis. 2020 Jul;12(7):3785-3795. doi: 10.21037/jtd.2019.08.63. PMID: 32802458; PMCID: PMC7399437
Chong YC, Toh TB, Chan Z, Lin QXX, Thng DKH, Hooi L, Ding Z, Shuen TWH, Toh HC, Dan YY, Bonney GK, Zhou L, Chow P, Wang Y, Benoukraf T, Chow EK, Han W. Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression. Hepatol Commun. 2020 Jul 27;4(9):1362-1381. doi: 10.1002/hep4.1559. PMID: 32923839; PMCID: PMC7471427
Ahl PJ, Hopkins RA, Xiang WW, Au B, Kaliaperumal N, Fairhurst AM, Connolly JE. Met-Flow, a strategy for single-cell metabolic analysis highlights dynamic changes in immune subpopulations. Commun Biol. 2020 Jun 12;3(1):305. doi: 10.1038/s42003-020-1027-9. PMID: 32533056; PMCID: PMC7292829
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PMID: 32402160
Ho LP, Teo Bryan YW, Linn YC, Tan PH, Jabed I, Toh HC, Yeoh KW. Unifying framework for acute resolution, malignancy and autoimmunity. Scand J Immunol. 2020 May;91(5):e12869. doi: 10.1111/sji.12869. Epub 2020 Feb 21. PMID: 32017146.
Ang WX, Ng YY, Xiao L, Chen C, Li Z, Chi Z, Tay JC, Tan WK, Zeng J, Toh HC, Wang S. Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts. Mol Ther Oncolytics. 2020 May 4;17:421-430. doi: 10.1016/j.omto.2020.04.013. PMID: 32462079; PMCID: PMC7240063
Liu WN, Fong SY, Tan WWS, Tan SY, Liu M, Cheng JY, Lim S, Suteja L, Huang EK, Chan JKY, Iyer NG, Yeong JPS, Lim DW, Chen Q. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. Cancers (Basel). 2020 Apr 22;12(4):1025. doi: 10.3390/cancers12041025. PMID: 32331230; PMCID: PMC7225949
Chuah S, Chew V. High-dimensional immune-profiling in cancer: implications for immunotherapy. J Immunother Cancer. 2020 Feb;8(1):e000363. doi: 10.1136/jitc-2019-000363. PMID: 32034066; PMCID: PMC7057482
Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel). 2019 Dec 3;11(12):1926. doi: 10.3390/cancers11121926. PMID: 31816940; PMCID: PMC6966558
Ding Z, Ericksen RE, Escande-Beillard N, Lee QY, Loh A, Denil S, Steckel M, Haegebarth A, Shuen TWH, Chow P, Toh HC, Reversade B, Gruenewald S, Han W. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J Hepatol. 2020 Apr;72(4):725-735. doi: 10.1016/j.jhep.2019.10.026. Epub 2019 Nov 11. PMID: 31726117
Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH. Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. Front Immunol. 2019 Sep 4;10:2093. doi: 10.3389/fimmu.2019.02093. PMID: 31552039; PMCID: PMC6738266
Jin Y, Lee WY, Toh ST, Tennakoon C, Toh HC, Chow PK, Chung AY, Chong SS, Ooi LL, Sung WK, Lee CG. Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma. J Transl Med. 2019 Aug 20;17(1):273. doi: 10.1186/s12967-019-2025-x. PMID: 31429776; PMCID: PMC6701074
Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, Lim TKH, Yeong J, Toh HC, Lee SY, Chan CY, Goh BK, Chung A, Heikenwälder M, Ng IO, Chow P, Albani S, Chew V. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019 May;68(5):916-927. doi: 10.1136/gutjnl-2018-316510. Epub 2018 Jul 3. PMID: 29970455
Lim CJ, Chew V. Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. Semin Liver Dis. 2020 May;40(2):131-142. doi: 10.1055/s-0039-3399534. Epub 2019 Dec 6. PMID: 31810095
Ericksen RE, Lim SL, McDonnell E, Shuen TWH, Vadiveloo M, White PJ, Ding Z, Kwok R, Lee P, Radda GK, Toh HC, Hirschey MD, Han W. Loss of BCAA Catabolism during Carcinogenesis Enhances mTORC1 Activity and Promotes Tumor Development and Progression. Cell Metab. 2019 May 7;29(5):1151-1165.e6. doi: 10.1016/j.cmet.2018.12.020. Epub 2019 Jan 17. PMID: 30661928; PMCID: PMC6506390